Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians

Adriana Foster, Zixuan Wang, Manzoor Usman, Edna Stirewalt, Peter Buckley

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.

Original languageEnglish (US)
Pages (from-to)965-973
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume3
Issue number6
StatePublished - Dec 1 2007

Fingerprint

Pharmacogenetics
Antipsychotic Agents
Precision Medicine
Preventive Medicine
Movement Disorders
Therapeutics
Psychotic Disorders
Cytochrome P-450 Enzyme System
Weight Gain
Research

Keywords

  • Adverse effects
  • Antipsychotic drugs
  • Pharmacogenetics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Pharmacogenetics of antipsychotic adverse effects : Case studies and a literature review for clinicians. / Foster, Adriana; Wang, Zixuan; Usman, Manzoor; Stirewalt, Edna; Buckley, Peter.

In: Neuropsychiatric Disease and Treatment, Vol. 3, No. 6, 01.12.2007, p. 965-973.

Research output: Contribution to journalReview article

Foster, A, Wang, Z, Usman, M, Stirewalt, E & Buckley, P 2007, 'Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians', Neuropsychiatric Disease and Treatment, vol. 3, no. 6, pp. 965-973.
Foster, Adriana ; Wang, Zixuan ; Usman, Manzoor ; Stirewalt, Edna ; Buckley, Peter. / Pharmacogenetics of antipsychotic adverse effects : Case studies and a literature review for clinicians. In: Neuropsychiatric Disease and Treatment. 2007 ; Vol. 3, No. 6. pp. 965-973.
@article{b1e823ac5e5f427492d5f690617fa8a0,
title = "Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians",
abstract = "There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.",
keywords = "Adverse effects, Antipsychotic drugs, Pharmacogenetics",
author = "Adriana Foster and Zixuan Wang and Manzoor Usman and Edna Stirewalt and Peter Buckley",
year = "2007",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "965--973",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Pharmacogenetics of antipsychotic adverse effects

T2 - Case studies and a literature review for clinicians

AU - Foster, Adriana

AU - Wang, Zixuan

AU - Usman, Manzoor

AU - Stirewalt, Edna

AU - Buckley, Peter

PY - 2007/12/1

Y1 - 2007/12/1

N2 - There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.

AB - There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.

KW - Adverse effects

KW - Antipsychotic drugs

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=38149131166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149131166&partnerID=8YFLogxK

M3 - Review article

C2 - 19300635

AN - SCOPUS:38149131166

VL - 3

SP - 965

EP - 973

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 6

ER -